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Abstract
Protein phosphatase 2A (PP2A), the major serine/threonine phosphatase in eukaryotic cells, is a heterotrimeric protein
composed of structural, catalytic, and targeting subunits. PP2A assembly is governed by a variety of mechanisms, one of
which is carboxyl-terminal methylation of the catalytic subunit by the leucine carboxyl methyltransferase LCMT1. PP2A is
nearly stoichiometrically methylated in the cytosol, and although some PP2A targeting subunits bind independently of
methylation, this modification is required for the binding of others. To examine the role of this methylation reaction in
mammalian tissues, we generated a mouse harboring a gene-trap cassette within intron 1 of Lcmt1. Due to splicing around
the insertion, Lcmt1 transcript and LCMT1 protein levels were reduced but not eliminated. LCMT1 activity and methylation
of PP2A were reduced in a coordinate fashion, suggesting that LCMT1 is the only PP2A methyltransferase. These mice
exhibited an insulin-resistance phenotype, indicating a role for this methyltransferase in signaling in insulin-sensitive tissues.
Tissues from these animals will be vital for the in vivo identification of methylation-sensitive substrates of PP2A and how
they respond to differing physiological conditions.
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Introduction
Tightly controlled protein phosphorylation and dephosphory-
lation is vital to effective cellular function in mammalian cells [1].
The extent of phosphorylation at a given site is balanced by the
opposing actions of protein kinases and protein phosphatases [2].
Over one-third of the murine and human proteome is believed to
be phosphorylated by the 540 murine (518 human) protein kinases
at tyrosine, serine, and threonine residues [3,4,5]. These
phosphorylation events overwhelmingly occur on serines and
threonines with a ratio of approximately 1800:200:1 for pS:pT:pY
modifications, respectively [6]. Tyrosine phosphorylation, cata-
lyzed by protein tyrosine kinases (coded for by 90 genes in the
human genome) is opposed by four families of protein tyrosine
phosphatases (encoded by 107 distinct genes, with each phospha-
tase largely specific for a single substrate) [7,8]. In contrast to the
biological strategy evolved for the removal of tyrosine phosphor-
ylation, the catalysis of phosphate removal from the thousands of
substrates of the 428 human protein serine/threonine kinases is
catalyzed by only ten protein serine/threonine phosphatases [9].
Unlike a typical tyrosine phosphatase, the major serine/threonine
protein phosphatase (PP2A) recognizes a wide variety of substrates
involved in many signaling cascades and cellular functions [10].
In order to control such a variety of cellular mechanisms, PP2A
is regulated through multiple control points: posttranslational
modifications, small molecule activators and inhibitors, the
presence of regulatory subunits, as well as other types of
protein–protein interactions [10]. A basic level of substrate control
is provided by the composition of the heterotrimeric subunits
composing PP2A [11]. PP2A exists in the cytosol primarily as a
heterodimer consisting of a catalytic (C) and a scaffolding (A)
subunit, to which a variety of targeting or regulatory (B) subunits
associate, altering the specificity of the phosphatase [12,13]. The
complexity of PP2A composition arises from the enormity of
distinct PP2A holoenzyme assemblies formed by proteins coded by
the two similar yet non-redundant genes responsible for the
catalytic subunit [14,15], the two non-redundant genes coding for
the scaffolding subunit [16,17], and the four unrelated families of
regulatory subunits encoded by multiple genes with a variety of
splice variants giving rise to at least 23 different B subunits
[10,11,18,19,20]. The vast array of subunits available for
integration into PP2A holoenzymes are themselves regulated by
spatial and temporal means as well as a strict regimen of
posttranslational modifications [10,21].
Three covalent modifications of particular interest occur on the
C-terminal ‘‘tail’’ of the catalytic subunit, a 6 residue sequence
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(TPDYFL) which is unstructured and yet highly conserved
[10,13,22,23,24]. Phosphorylation of residue T304 and Y307
has been associated with PP2A deactivation [25,26,27,28,29],
while methylation of the C-terminal carboxyl moiety of L309
alters the assembly and activation of PP2A [30,31,32]. Moreover,
genetic experiments have revealed that a mutant PP2A with a
phosphomimetic residue replacing Y307 is unable to be methyl-
ated at L309, yet the same mutations at T304 allows methylation,
suggesting likely interplay between these modifications [33,34].
Charge neutralization may play an important role in the effects of
C-terminal methylation on PP2A structure and function
[13,23,24,35].
Carboxyl methylation of the C-terminus at L309 is a dynamic
process catalyzed by the leucine carboxyl methyltransferase
LCMT1 [33,36,37] and the predominantly nuclear methylesterase
PME-1 [38,39]. LCMT1 is a class 1 S-adenosylmethionine-
dependent methyltransferase with PP2A as its only known
substrate [12,13]. Although a knockout of Lcmt1 in mice was
found to be lethal during embryonic development, hindering its
study [40], site-specific mutational analysis of the PP2A catalytic
subunit has revealed that L309 methylation is necessary for
binding of the Ba (PR55) subunit [41], and positively influences
the binding of the B9 family members [42], subunits thought to
protect against oncogenic transformation [43]. On the other hand,
methylation appears to decrease the binding of polyoma middle T
and a4 binding [33,44,45,46]. Other B subunit families appear to
bind irrespective of C-terminal methylation [34,47,48].
The complexity of the interaction between LCMT1 and PP2A
has been demonstrated in several previous studies. Neither PP2A
loss-of-function mutants, in which active site residues are mutated
[33], nor wild-type PP2A that has been subjected to small
molecule or protein inhibitors [49,50], can be methylated by
LCMT1. Additionally, peptides mimicking the C-terminal tail of
PP2A are not substrates of LCMT1 [37]. Recently, co-crystal
structures of LCMT1 with the catalytic subunit of PP2Ac shed
light on this complex protein interaction, revealing not only
surface interactions between the active site of the methyltransfer-
ase and the C-terminal tail of PP2A, but also an interaction
between a domain of LCMT1 and the active site of PP2A [13].
These studies suggest an additional role for the methyltransferase
in minimizing the activity of free PP2A catalytic subunit by
selectively enhancing methylation of the activated PP2A and
conversion into appropriate trimeric holoenzymes [13].
In an attempt to elucidate the role of LCMT1 and PP2A
methylation in higher organisms, we report the generation of an
Lcmt1 hypomorphic mouse model, detailing the biochemical as
well as the phenotypic effects of reduced LCMT1 activity.
Although disrupting Lcmt1 was previously found to be lethal in
an Lcmt1 gene-trap mouse [40], in this report we demonstrate
partial LCMT1 activity in mice with a distinct Lcmt1 gene trap
mutation. In these mice, splicing around the insertional mutation
leads to the production of intact Lcmt1 transcripts and allows
homozygous mice to survive embryonic development. We show
that Lcmt1 expression is affected in a tissue-dependent manner,
with the largest decreases observed in cardiac and skeletal muscle,
and smaller decreases in brain, liver, and kidney. Decreases in
PP2A methylation as well as concomitant increases in demethyl-
ation were observed in the Lcmt1 hypomorphic mice, along with
decreases in glucose tolerance and increases in glucose-stimulated
insulin secretion.
Methods
Ethics Statement
This study was performed in accordance with animal use
protocols approved by the University of California at Los Angeles
Chancellor’s Animal Research Committee (Protocol 1993-109-
63).
Animal Husbandry
Mice were kept on a 12-h light/dark cycle and allowed ad libitum
access to water and NIH-31 7013 chow (18% protein, 6% fat, 5%
fiber, Harlan Teklad, Madison, WI). Mice were housed in same-
sex cages with two or three other mice. Breeding animals were
housed with one partner. Animals were genotyped at 18 days of
age and weaned at 21 days of age.
Lcmt12/2 Mice
Lcmt1+/2 mice were generated with a BayGenomics mutant
embryonic stem cell line CSC099 containing a gene-trap insertion
in intron 1 of Lcmt1 [51]. Mice used in this study were backcrossed
at least three times to C57BL/6 mice.
Genotyping
Tail tip biopsies were used for genotyping; DNA was prepared
with Allele-In-One Mouse Tail Direct Lysis Buffer (Allele
Biotechnology, San Diego, CA) according to the manufacturer’s
instructions. The site of gene-trap cassette insertion was identified
with PCR reactions of intron 1 of Lcmt1. Primers were
subsequently designed flanking this site of insertion (forward:
CCTTTCTGGGTGAGCTCTTG, reverse: AGATGAG-
CATCGGAATCTGG; 1899 nucleotide product) as well as
primers within the gene-trap cassette itself (forward: AT-
TATTTGCCCGATGTACGC, reverse: ACATCCAGAGG-
Table 1. Source of antibodies and immunoblotting protocols.
Target Name Source Dilution Incubation time Temperature Polypeptide size
deMe-PP2A a-PP2A, clone 1D6, 05-421 Millipore 1:10,000 1 h 25uC 36 kDa
LCMT1 a-LCMT1 (4A4) (ab77754) Abcam 1:10,000 1 h 25uC 38 kDa
GAPDH a-GAPDH (14C10) Cell Signaling 1:40,000 1 h 25uC 37 kDa
beta-actin a-beta actin prepared in rabbit (non-
commercial)
Gift from Dr. Emil
Reisler
1:40,000 1 h 25uC 45 kDa
mouse IgG a-mouse IgG prepared in rabbit, HRP
secondary #7076
Cell Signaling 1:100,000 1 h 25uC NA
rabbit IgG a-rabbit IgG prepared in goat HRP
conjugated secondary (ab721))
Abcam 1:100,000 1 h 25uC NA
doi:10.1371/journal.pone.0065967.t001
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CACTTCACC; 524 nucleotide product) to genotype these
animals. The PCR program used for genotyping consisted of an
initial denaturation step of 95uC for 5 min, followed by repeated
denaturation at 95uC for 1 min, primer annealing at 61uC for
1 min, and elongation at 72uC for 3 min for 35 cycles, followed by
a final elongation step at 72uC for 10 min.
Southern Blotting
Southern blotting was performed by the UC-Irvine Transgenic
Mouse Facility. Briefly, a mouse tail biopsy was collected and
DNA was extracted utilizing phenol chloroform extraction.
Genomic DNA was digested with the AflII restriction enzyme
which does not cut within the gene trap cassette and should yield a
9,812 base pair product containing the gene trap insert and
adjacent genomic DNA. After agarose gel electrophoresis, DNA
fragments were transferred to a membrane and hybridized with a
32P-labeled probe recognizing the b-Geo insert. The probe
sequence was as follows: gggcgcccggttctttttgtcaagacc-
gacctgtccggtgccctgaatgaactgcaggacgaggcagcgcggctatcgtggctggc-
cacgacgggcgttccttgcgcagctgtgctcgacgttgtcactgaagcgggaagg-
gactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctcctgcc-
gagaaagtatccatcatggctgatgcaatgcggcggctgcatacgcttgatccggc-
tacctgcccattcgaccaccaagcgaaacatcgcatcgagcgagcacgtactcggatg-
gaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgccagcc-
gaactgttcgccaggctcaaggcgcgcatgcccgacggcgatgatctcgtcgtgacc-
catggcgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctggattcatc-
gactgtggccggctgggtgtg.
RNA Isolation, cDNA Generation, and qPCR
All instruments and bench space were cleaned using RNase
Away (Fischer, Torrance, CA). Mice were fasted overnight and
sacrificed by carbon dioxide asphyxiation. Tissues were dissected
and immediately frozen in liquid nitrogen. Approximately 0.1 g of
each tissue was homogenized on ice in 1 ml of tri-reagent
(Molecular Research Center, Cincinnati, OH), a commercially
available guanidinium thiocyanate-phenol-chloroform mixture
[52], using a Polytron homogenizer equipped with a PTA-7
generator. Samples were pulsed seven times for 30 s each with
1 min between pulses to prevent heating of the sample. Samples
Figure 1. Genomic confirmation of Lcmt12/2 animals. Panel A: Southern blot showing a single band of 9.8 kDa corresponding to the predicted
AflII restriction product. No other bands were seen at other sizes in Lcmt12/2 gel lane or in the gel lanes of WT DNA samples. Panel B: Schematic of
Lcmt1+/+ and Lcmt12/2 genomic DNA showing the position of the gene-trap insertion, PCR primers, and AflII restriction sites flanking the gene trap
cassette. Panel C: Primers flanking the gene-trap cassette insertion site (WT primers) amplify an 1899-bp product when the gene trap is absent;
primers inside the gene trap cassette (KO primers) amplify a 524-bp product when the gene trap is present (see ‘‘Methods’’). When the 8.6-kb gene-
trap cassette is present, WT primer amplification is prevented.
doi:10.1371/journal.pone.0065967.g001
Figure 2. Initial intercrosses of Lcmt1+/2 mice yield lower-than-
expected numbers of homozygous offspring. Pups were counted
on the day they were born and genotyped at 18 days of age.
doi:10.1371/journal.pone.0065967.g002
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were subsequently centrifuged at 20,0006 g for 10 min and the
floating layer and pellet removed. A volume of chloroform
equivalent to 1/5 of the volume of tri-reagent used was
subsequently added to the supernatant, shaken, and further
centrifuged at 20,0006 g. The aqueous phase was saved and
added to an equivalent volume of isopropanol. The sample was
then centrifuged again for 7 min at 20,0006 g, decanted, further
washed with 70% ethanol, and centrifuged again for 5 min at
20,0006 g. After decanting the ethanol, the RNA pellet was dried
and resuspended in 20 ml of RNase-free water (Qiagen, Valencia,
CA). Samples were checked for purity by insuring the absorbance
ratio at 260 nm/280 nm was at least 1.9, and for degradation by
the presence of intact 18S and 28S rRNA after separation on a 1%
agarose gel and staining with ethidium bromide. The RNA pellet
was treated with a TURBO DNA-free Kit (Applied Biosystems,
Carlsbad, CA) to remove contaminating DNA. Total cDNA was
Figure 3. Lcmt1 transcript quantitation in wild-type and Lcmt12/2 mouse tissues. Panel A: Lcmt1 transcript levels from five tissues,
measured using primers flanking exons 1 and 2, and exons 2 and 3 as described in the ‘‘Methods’’ section, were normalized to b-2 microglobulin
transcript levels measured in the same tissue. DCt values are displayed above each column. Values were averaged from tissues prepared from three
wild-type and three knockout mice; all qPCR determinations were performed in duplicate. Errors bars show the standard deviation. Panel B: Lcmt12/2
transcript levels as a percent of Lcmt1+/+ transcript levels. Error bars represent the standard deviation. Asterisks indicate where the decrease in
Lcmt12/2 transcript levels compared to those of wild-type mice are significant at a p value of less than 0.05 by the Student’s t-test. Panel C: the upper
schematic shows the generation of full-length Lcmt1 mRNA in wild-type mice while the middle schematic shows the generation of a truncated
transcript in Lcmt12/2 mice. The lower schematic shows how alternative splicing can skip over the gene trap cassette to produce a full-length mRNA
transcript.
doi:10.1371/journal.pone.0065967.g003
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generated using a RETROscript kit (Applied Biosystems). cDNA
was plated in a 384-well plate with primers within Lcmt1 exons 1
and 2 (forward: ACTTGGACGACGAGGGAGT; reverse:
GATGCTCGATGTACGGATCA), as well as primers on Lcmt1
exons 2 and 3 (forward: ATGATCCGTACTCGAGCATC;
reverse: CTGACTGACACCATGAACTCG), as well as primers
on the B2m gene (forward: ATGATCCGTACTC-
GAGTGGTGCTTGTCTCACTGACC; reverse:
TATGTTCGGCTTCCCATTCT). The qPCR experiment was
performed on a 7900 HT instrument (Applied Biosystems) and
data was analyzed using the 22DCt method [53].
Western Blotting
Mice were fasted overnight and euthanized in a CO2 chamber.
Tissues were dissected, weighed, and to each gram of tissue 3 ml of
sucrose buffer was added (250 mM sucrose, 10 mM Tris base,
1 mM EDTA, adjusted to pH 7.4 with HCl, with phosphatase
(HALT, Thermo-Pierce, Rockford, IL) and protease inhibitors
(Complete, Roche, Mannheim, Germany)). Homogenization was
performed using a Polytron homogenizer with a PTA-7 generator
using seven pulses of 30 s with 1 min on ice between pulses.
Extracts were then centrifuged at 20,0006 g and the supernatants
were stored at 280uC. Protein in an aliquot of these soluble
extracts was precipitated with trichloroacetic acid and quantified
by the Lowry method [54]. Aliquots containing 20 mg of protein
were added to 10 ml of a 26SDS-sample loading buffer (100 mM
Tris-HCl, pH 6.8, 200 mM b-mercaptoethanol, 4% SDS, 0.1%
bromophenol blue, 20% glycerol) and then brought to a final
volume of 20 ml with water and heated for 5 min at 100uC. Unless
otherwise indicated, the samples were then loaded into 12-well,
10 cm610 cm, 4–12% RunBlue SDS gels (Expedeon, San Diego,
CA) in an Invitrogen XCell SureLock Mini-Cell apparatus along
with rainbow molecular weight markers (RPN-800V, GE
Healthcare, Buckinghamshire, England). Electrophoresis was
performed at 180 V for 1 h. Proteins were transferred from gels
to PVDF membranes (Amersham Hybond-P, GE Healthcare) by
electrophoresis at 25 V for 3 h using the Invitrogen Blot Module
and NuPAGE transfer buffer (Invitrogen, Grand Island, NY).
Membranes were blocked overnight with 5% bovine serum
albumin and then incubated with primary antibodies diluted in
TBS-T buffer (50 mM Tris, 150 mM NaCl, 0.05% Tween 20,
pH 7.4) as described in Table 1. After the blot was washed in
TBS-T buffer, it was incubated with dilutions of horseradish
peroxidase–labeled secondary antibodies as described in Table 1.
Peroxidase activity was visualized after treating the blot with ECL
Prime Chemiluminescent Agent (GE Healthcare) and detected on
Hyblot CL film (Denville, Metuchen, NJ). Every attempt was
made to capture exposures within the linear film response. Film
densitometry was performed using ImageJ densitometry software.
Figure 4. Quantitation of LCMT1 levels in tissues of Lcmt12/2 animals compared to wild-type controls. Panel A: Representative Western
blots of tissue extracts with antibodies against LCMT1. Antibodies to b-actin were used as a loading control. All samples were electrophoresed on the
same gel along with protein ladder standards. Panel B: Summary of results from experiments with extracts from three wild-type and three Lcmt12/2
mice. Densitometry was used to normalize LCMT1 levels to actin. The ratio of Lcmt12/2 to Lcmt1+/+ signals were then plotted with the error bars
indicating the standard deviation of three experiments. In each case, extracts of wild-type and knockout tissues were electrophoresed on the same
gel as shown in Panel A. Asterisks indicate significant decreases in expression (p value less than 0.05) by Student’s t-test.
doi:10.1371/journal.pone.0065967.g004
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In Vitro PP2A Methylation Assay
LCMT1 activity in soluble mouse brain extracts was deter-
mined by taking advantage of the base-lability of methyl esters in a
vapor diffusion assay similar to that described previously [55].
Briefly, tissues were collected, homogenized in a sucrose buffer,
and processed as described for Western blot analysis above.
Protein concentration was determined by the Lowry method after
protein precipitation with trichloroacetic acid [54]. The in vitro
methylation assay was performed by adding 2.5 ml of S-adenosyl-L-
[methyl-3H]methionine (1 mCi/1.8 ml; 78 Ci/mmol; PerkinElmer)
to 100 mg of protein extract in a 100 mM pH 7.4 Tris-HCl buffer
in a total volume of 25 ml. This was incubated at 37uC for 1 h.
This reaction was quenched by adding 26 sample loading buffer
(100 mM Tris-HCl, pH 6.8, 200 mM b-mercaptoethanol, 4%
SDS, 0.1% bromophenol blue, 20% glycerol) and subsequent
heating to 100uC for 5 min. These extracts were then loaded onto
4–12% RunBlue SDS gels (Expedeon, San Diego, CA) and
separated by electrophoresis alongside molecular weight markers.
The gel was then stained with Coomassie Brilliant Blue and the
region corresponding to proteins of 31–45 kDa was cut into three
slices. These slices were added to microfuge tubes containing
100 ml of 2 M NaOH to release the carboxyl methyl esters as
methanol. These uncapped tubes were placed in scintillation vials
containing 5 ml of scintillation fluid (Safety-Solve, RPI, Mount
Prospect, IL) such that the scintillation fluid never directly
contacted the base-treated sample. The vials were then tightly
capped and incubated overnight to allow the diffusion of the
released [3H]methanol into the fluor. Samples were counted three
times with a liquid scintillation counter. A parallel lane of the
molecular weight ladder was cut and counted as a negative
control.
Glucose Tolerance and Glucose-Stimulated Insulin
Secretion Assays
Mice were fasted overnight for 15 h by placing them in fresh
cages with water but without food. Blood glucose measurements
were recorded with an Accucheck Active blood glucose meter and
Accucheck Active glucose test strips (Roche, Mannheim, Ger-
Figure 5. Quantitation of the steady state methylation level of PP2A in tissues of Lcmt12/2 and Lcmt1+/+mice. Panel A–D: Tissue extracts
from four wild-type and four knockout animals were treated either with 0.1 M NaOH for 1 min at room temperature to cleave methyl esters followed
by addition of 0.1 M HCl and 0.5 M Tris-HCl, pH 7.4 to neutralize the solution (NaOH +), or a previously neutralized buffer containing the
aforementioned solutions as a control (NaOH 2). Polypeptides from these extracts were then separated by SDS-PAGE using 17-well, 4–12% Bis-Tris
NuPAGE gels (Invitrogen), transferred to PVDF membranes, and incubated with clone 1D6 antibodies selective for the demethylated catalytic subunit
of PP2A, and antibodies to GAPDH as a loading control. These procedures are described in detail in ‘‘Methods’’. Panels E–H: The percent of the PP2A
catalytic subunit that is demethylated was calculated as described by Yu et al. [33]. The columns represent the average 6 the standard deviation for
the four Lcmt12/2 and four Lcmt1+/+ mice shown in Panel A–D. Statistical significance at the level of p less than 0.05 was determined by the Student’s
t-test and is denoted by the asterisk.
doi:10.1371/journal.pone.0065967.g005
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many), requiring,1–2 ml of blood per measurement. The tail vein
of each animal was nicked with a fresh scalpel, and a glucose test
strip immediately spotted with blood and analyzed. From the same
tail nick, another 40 mL of blood was collected into 50 ml of PBS-
EDTA anticoagulation buffer (10 mM sodium phosphate,
5.4 mM disodium EDTA acid (2 mg/ml), 137.9 mM sodium
chloride), immediately placed on ice and saved for the insulin
assay. Following this initial measurement, animals were orally
administered a bolus of 0.5 g/ml D-glucose dissolved in water
corresponding to 2 g glucose per kilogram of body weight. Fresh
blood was collected for the insulin assay and glucose levels
analyzed at 5, 15, 30, and 60 min following the glucose load. The
collected blood samples were spun at 4uC at 1,0006g for 10 min
to pellet cells and the plasma insulin level was measured in the
supernatant using a Rat/Mouse Insulin ELISA kit (Catalog #
EZRMI-13K, EMD Millipore, Billerica, MA) according to the
manufacturer’s instructions.
Results
Generation and characterization of a Lcmt1 hypomorphic
mouse model
High-percentage male chimeric mice were generated with a
BayGenomics embryonic stem cell line CSC099 [51] containing
an insertional mutation in intron 1 of Lcmt1 (identified by 59-
RACE). Chimeric mice were bred to create Lcmt1+/2 mice. The
precise location of the insertional mutation was determined with a
PCR-based screening system using forward primers within intron
1 and a reverse primer on the gene-trap cassette. Sequencing of
the PCR products revealed that the gene-trap cassette was located
19,455 nucleotides into intron 1, or at position 19,729 of the gene
(counting from the transcriptional start site and the first base of the
initiating ATG codon designated as position 168). Sequencing of
the insertion site additionally revealed the insertion of 3 exogenous
nucleotides at the 59 end of the insertion site as well as the
truncation of 194 nucleotides from the 59 end of the b-geo gene-
trap cassette. We confirmed a single non-concatenated gene trap
insertion in intron 1 of Lcmt1 by Southern blotting using a probe
within the gene trap cassette (Figure 1A and 1B). This experiment
confirmed the presence of the b-geo insert in Lcmt12/2 animals at
the predicted site. The absence of multiple bands indicates a single
gene trap cassette insertion and the size of the hybridizing band
rules out concatemers at the site of insertion. A control with wild-
type DNA yielded no signal. Genotyping was accomplished with
primers flanking the insertion site (that only amplify in absence of
gene trap) and with b-geo primers (that only amplify in presence of
the gene trap) (Figure 1C).
F1 heterozygous mice were backcrossed at least three times to
C57BL/6 mice. Homozygous mice were initially generated by
intercrossing heterozygotes; homozygous offspring were obtained
at a lower-than-predicted frequency (Figure 2). In part, the low
frequency of homozygous offspring probably was due to the death
of Lcmt12/2 embryos during development as many resorbing
embryos were observed at E9.5. Fewer than one pup was lost from
birth until the time of weaning at 18 days of age, so it is unlikely
that postnatal death accounted for the reduced frequency of
Lcmt12/2 mice. Lcmt12/2 mice that survived development
exhibited normal vitality and were fertile; intercrossing Lcmt12/2
Figure 6. Quantification of in vitro PP2A methylation. Extracts
from Lcmt12/2 and Lcmt1+/+ mice were incubated with [3H]AdoMet as
described in the ‘‘Methods.’’ The radioactive peak of [3H]methyl esters
corresponding to the position of the PP2A catalytic subunit at ,36 kDa
was quantified after the background (from a parallel lane of molecular
weight standards) was subtracted. Each column represents the mean of
three independent experiments utilizing tissue extracts from three
Lcmt12/2 and three Lcmt1+/+ mice. Error bars represent the standard
deviation. Asterisks indicate statistically-significant differences between
extracts from wild-type and knockdown mice (p value less than 0.05)
with the Student’s t-test.
doi:10.1371/journal.pone.0065967.g006
Figure 7. Decreased glucose tolerance in Lcmt12/2 mice. Male
and female mice were fasted overnight and administered 2 g of glucose
orally per kg body mass followed by measurement of whole blood
glucose levels as described in the ‘‘Methods.’’ Panel A: Results from three
wild-type and three knockout male mice. Error bars represent standard
deviation; asterisks indicate statistically-significant differences between
wild-type and knockout mice (p value less than 0.05) with the Student’s
t-test. Panel B: Results as in panel A but using 3 wild-type and 3
knockout female mice.
doi:10.1371/journal.pone.0065967.g007
Analysis of Hypomorphic Lcmt1 Mice
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65967
mice yielded litters of 5–8 pups. Lcmt12/2 mice were healthy and
had a normal lifespan.
The analysis of brain, heart, kidney, liver, and skeletal muscle
tissues from Lcmt12/2 mice revealed lower levels of Lcmt1
transcripts than in wild-type mice, but not the complete
elimination of transcripts that we had expected (Figure 3A).
Interestingly, the decrease in Lcmt1 transcripts appeared to be
tissue specific with kidney exhibiting the highest Lcmt1 expression
levels relative to wild-type mice at 58%, followed by brain at 48%,
liver at 37%, heart at 6% and skeletal muscle at just 3%
(Figure 3B). Analysis of the Lcmt1 primary genomic sequences as
well as that of the insertion site revealed that the splice donor site
on exon 1 of Lcmt1 is a non-consensus site. With the loss of a
branch site on the gene trap cassette, this leads to the in silico
prediction of partial splicing around the gene trap cassette
(Figure 3C) [56]. To rule out the presence of alternative
transcriptional start sites, we performed qPCR experiments,
comparing the production of PCR products using exon 2 and 3
primers with products obtained with exon 1 and 2 primers. Both
primer pairs yielded similar transcript levels via qPCR, implying
that the Lcmt1 transcripts were generated by splicing around the
gene-trap cassette. Had there been an alterative transcriptional
start site 39 of the insertional mutation, we would have expected to
find much higher Lcmt1 expression levels with the exon 2/3 primer
pair. These data indicate that the Lcmt12/2 mice are homozygotes
for a hypomorphic allele rather than for a bona fide knockout allele.
To confirm the presence of a normal-sized LCMT1 protein in
Lcmt12/2 animals, we immunoblotted tissue extracts from
Lcmt12/2 and Lcmt1+/+ mice with antibodies against LCMT1.
These experiments revealed that the LCMT1 protein was of
normal size but the quantity of the protein was decreased in a
tissue-specific fashion similar to that observed with Lcmt1 transcript
levels (Figure 4A; Figure S1). The largest decreases in expression
were observed in muscle and heart tissue with Lcmt12/2 animals
having LCMT1 protein levels of only about 13% and under 2% of
those in wild-type mice, respectively (Figure 4B). To ascertain the
relative levels of LCMT1 in heart tissue in Lcmt12/2 animals as
compared to wild-type controls, we performed additional blotting
using 100-fold higher concentrations of the primary LCMT1
antibody and a 24 h primary antibody incubation (Figure S2,
Panel A). These experiments showed that LCMT1 levels in
Lcmt12/2 heart tissue represent less than 1% of those of the wild
type (Figure S2; Panels B and C). Decreased expression of
LCMT1 protein level was also found in kidney, liver, and brain,
with levels in knockout tissues compared to wild-type tissues of
about 16%, 22%, and 46%, respectively (Figure 4). With the
exception of kidney, the relative LCMT1 expression appeared to
be consistent with the mRNA levels (Figure 3B). In wild-type mice,
LCMT1 protein was most abundant in brain, followed by muscle,
kidney, and liver; the lowest expression was observed in heart
(Figure 4). These levels correspond to those previously published in
a transcriptome study [57].
Lcmt12/2 animals display decreased methylation of PP2A
Decreased levels of LCMT1 in the Lcmt12/2 mice did not
appear to affect the cellular levels of the catalytic subunit of PP2A
but did reduce methylation of PP2A in brain, liver, and skeletal
muscle (Figure 5). Analysis of the steady-state level of demethyl-
ated PP2A by Western blotting indicated that the decrease in
methylation in Lcmt12/2 animals was statistically significant in
brain and skeletal muscle tissue. We detected no difference in the
steady state of the demethylated form of PP2A in heart, and a
statistically insignificant gain of demethylation in liver. Interest-
ingly, the largest decrease in LCMT1 expression in Lcmt12/2
animals was in heart although it appeared this did not alter
methylation of PP2A in this tissue. Lcmt1+/+ skeletal muscle tissue
was found to have an average steady-state methylation level of
about 77%, which was found to decrease to an average of about
59% in Lcmt12/2 animals. In brain, which was found to have
steady-state methylation of about 52%, we observed a drop to
about 15% in Lcmt12/2 animals.
An in vitro methyltransferase assay utilizing endogenous LCMT1
in cytosolic extracts revealed a similar decrease in PP2A
methylation (Figure 6). With the exception of extracts from
Figure 8. Male Lcmt12/2 animals display increased glucose-stimulated insulin secretion. Three wild-type and three knockout mice were
fasted overnight and administered 2 g of glucose per kg of body mass, followed by measurement of plasma insulin levels as described in the
‘‘Methods.’’ Error bars represent standard deviations; asterisks indicate statistically-significant differences between wild-type and knockout mice (p
value less than 0.05) with the Student’s t-test.
doi:10.1371/journal.pone.0065967.g008
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kidney, LCMT1 activity significantly decreased in Lcmt12/2
animals with the largest decreases of 62 to 68% in liver, heart,
and skeletal muscle. Brain exhibited a 41% reduction in
methylation.
Lcmt12/2 animals display increased insulin resistance
Because PP2A is involved in halting kinase cascades involved in
growth and cell signaling [58], we next looked at how a decrease in
PP2A methylation would affect insulin signaling. Lcmt12/2 mice
were fasted overnight for 15 h and subsequently given an oral
bolus of glucose (2 g/kg of body weight). Following the glucose
load, blood samples were obtained for blood sugar and insulin
measurements. Lcmt12/2 animals displayed significantly decreased
glucose tolerance (Figure 7) despite higher insulin levels (Figure 8),
a pattern often associated with insulin resistance [59,60,61].
Discussion
In this study, we present a novel mouse model that is
hypomorphic for LCMT1, the carboxyl-terminal protein methyl-
transferase that methylates PP2A, a major protein phosphatase.
We had expected that the gene-trap allele would yield a total
knockout, but splicing around the insertional mutation allowed for
some expression of Lcmt1 transcripts. Complete loss of LCMT1
results in embryonic lethality [40], but the hypomorphic Lcmt1
mice survived, making it possible to assess the effect of reduced
methylation of the PP2A catalytic subunit. Lcmt12/2 animals were
originally obtained at a lower-than-predicted frequency, but
surviving Lcmt12/2 mice appeared healthy and were fertile.
Lcmt12/2 mice had reduced levels of Lcmt1 transcripts as well as
decreased LCMT1 protein levels. Additionally, the only known
substrate of LCMT1, the protein phosphatase PP2A, displayed
reduced steady state methylation levels. Furthermore, in vitro
methyltransferase assays revealed decreased LCMT1 methyltrans-
ferase activity. In vitro methyltransferase experiments are compli-
cated by the relationship between the methyltransferase, PP2A,
and the presence of the PP2A-specific methylesterase PME-1. To
avoid demethylase activity, cellular membranes and the nucleus
was removed, making it possible to exclude the predominantly
nuclear PME-1. However, our results, as well as previous results
[33,43], suggest PP2A is largely methylated in vivo, suggesting in
vitro analyses utilizing [3H]AdoMet as a methyl donor may be
limited by the availability of nonmethylated PP2A substrate in
tissues.
PP2A has been associated with control of the major serine-
threonine kinases in growth and signaling and as such has long
been implicated in insulin signaling and the onset of insulin
resistance [62]. Several studies have implicated LCMT1 in the
direct control of insulin signaling. For example, glucose directly
controls PP2A methylation in isolated pancreatic b-cells [63] and
depletion of PP2A in pancreatic b-cells attenuates glucose-
stimulated insulin secretion [64]. It has also been suggested that
inhibition of PP2A is a leading cause of insulin resistance in heart
tissue [65,66]. Our findings indicate that decreased methylation of
PP2Ac due to decreased expression of LCMT1 contributes to
decreased glucose tolerance and increased glucose-stimulated
insulin secretion, lending additional support to the previous
findings.
Significant evidence exists implicating a role for PP2A in the
onset of Alzheimer’s disease and the formation of hyperpho-
sphorylated tau in neurofibrillary tangles [67,68,69]. Endogenous
peptide inhibitors of PP2A are increased in brains of Alzheimer’s
disease patients [70], implicating loss of phosphatase function in
the disease. Later, it was discovered that PP2A influenced tau
phosphorylation both directly by catalyzing tau dephosphorylation
and indirectly through regulation of GSK-3b [71], one of the
major tau kinases [72]. Of interest to this study, experiments in
animal models showed that adding a methyltransferase inhibitor
was capable of inducing the tau hyperphosphorylation [73].
Further evidence suggesting a correlation between tau hyperpho-
sphorylation and reduced methylation of PP2A arose from
evidence suggesting high plasma homocysteine levels correlated
with demethylated PP2A and Alzheimer’s disease [74], and that
downregulation of LCMT1 correlated with tau hyperphosphor-
ylation [68]. Increased expression of LCMT1 in neuroblastoma
cells has also been shown to alter actin assembly, promoting tau-
related processes and inducing neuritogenesis [75]. In humans,
however, despite evidence suggesting a role for LCMT1 and PP2A
in Alzheimer’s disease [68,76], genetic variation of these genes did
not appear to alter risk for late-onset Alzheimer’s disease [77].
Mice expressing a dominant-negative version of PP2A containing
an L309A mutation have been shown to exacerbate tauopathies
when backcrossed with neurofibrillary tangle-forming mice
containing a P301L mutation in tau [78]. Although we investi-
gated this finding by blotting with antibodies specific to hyperpho-
sphorylated tau in neurofibrillary tangles, we did not observe
significant differences between Lcmt12/2 and Lcmt1+/+ animals
(data not shown). However, because the animals utilized in this
study were under 100 days of age, changes in Lcmt12/2 tau brain
chemistry could become apparent later in animal life, a possibility
that we have not investigated.
Dysregulation of PP2A has been associated with cellular
proliferation and oncogene transformation [79]. Specifically,
methylation-sensitive subunits are implicated in controlling cell
growth and survival [80,81,82,83]. Recently, it has been suggested
that viral proteins can induce oncogenic transformation through
the replacement of methylation-sensitive PP2A B subunits with
methylation-independent viral proteins [84]. This replacement
may circumvent the antigrowth and antiproliferative effects of
methylation-sensitive PP2A heterotrimers and suggests that
reduced LCMT1 activity could contribute to oncogenic transfor-
mation and cancer [43]. Our observations of the hypomorphic
Lcmt12/2 mouse model over a period of several years have not
provided any evidence for an increased frequency of externally
visible tumors. However, we cannot exclude changes in the rate of
spontaneous oncogenic transformations and oncogenic growth in
the hypomorphic Lcmt1 mice.
Supporting Information
Figure S1 Quantitation of LCMT1 levels in tissues of
Lcmt12/2 animals compared to wild-type controls.
Polypeptides were separated from mouse tissue extracts and
Lcmt1 levels were measured by Western blotting as described in
Figure 4. Data are shown from all four of the replicate experiments
with multiple exposures to obtain densitometric traces in the linear
range that were used in the quantitation in Figure 4.
(TIF)
Figure S2 Quantitation of LCMT1 levels in heart tissue
of Lcmt12/2 animals compared to wild-type controls.
Panel A. Four wild-type and four knockout heart lysates were
blotted for LCMT1 and GAPDH (loading control). Three
exposures are shown to obtain the KO and WT LCMT1 signals
in the linear range of the film. Panel B: Quantitation of signals by
densitometry using ImageJ software is shown with the y-axis
reflecting arbitrary density units. Panel C: the KO LCMT1
density is shown as a percent of WT signal for the 3 independent
exposures. Because we did not capture KO and WT signals within
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the linear range of a single film exposure, we can only conclude
that LCMT1 in the heart of knockout animals is present at less
than 1% of the level in wild-type animals.
(TIF)
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